Breakthroughs in Triple-Negative Breast Cancer (TNBC) Management
Triple-Negative Breast Cancer (TNBC) is a subtype of breast cancer lacking estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression. Comprising 15–20% of breast cancers, TNBC is typically high-grade, affecting mainly premenopausal women, and individuals with inherited gene alterations, such as the Breast Cancer Susceptibility Genes 1and 2 (BRCA 1and 2) mutations. At diagnosis the tumor demonstrates aggressive biological behavior with a proclivity to be higher grade, often has lymph node involvement at diagnosis, and a tendency to metastasize even after curative treatment. TNBC has a poor prognosis when compared with other Breast cancer subtypes.